Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; pp. 1357 - 1359
Main Authors Vogl, Dan T., Atrash, Shebli, Holstein, Sarah A., Nadeem, Omar, Benson, Don M., Suryanarayan, Kaveri, Liu, Yuyin, Collins, Sabrina, Parot, Xavier, Kaufman, Jonathan L.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text

Cover

More Information
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-162253